分化型甲状腺癌风险分层的新见解。
New insights in risk stratification of differentiated thyroid cancer.
机构信息
aDivision of Metabolism, Endocrinology and Diabetes bDivision of Metabolism, Endocrinology and Diabetes, and Hematology/Oncology, Department of Medicine, Ann Arbor, Michigan, USA.
出版信息
Curr Opin Oncol. 2014 Jan;26(1):1-7. doi: 10.1097/CCO.0000000000000022.
Abstract
PURPOSE OF REVIEW
Numerous staging and scoring systems exist for differentiated thyroid cancer (DTC), but all harbor limitations. This has prompted investigation for new factors with prognostic implications for DTC.
RECENT FINDINGS
Several new factors that may be involved in DTC risk stratification have emerged, such as thyroid stimulating hormone and molecular markers. In addition, others are controversial and being challenged, such as age, sex and lymph node involvement.
SUMMARY
The purpose of this review is to present recent updates in the literature on new potential risk stratification predictors for DTC.
摘要
目的综述
分化型甲状腺癌（DTC）有许多分期和评分系统，但都存在局限性。这促使人们研究新的因素，以寻找对 DTC 具有预后意义的因素。
最近的发现
已经出现了一些可能涉及 DTC 风险分层的新因素，例如促甲状腺激素和分子标志物。此外，还有一些因素存在争议并受到质疑，如年龄、性别和淋巴结受累。
总结
本文旨在介绍 DTC 新的潜在风险分层预测因子的最新文献更新。
相似文献
1
New insights in risk stratification of differentiated thyroid cancer.分化型甲状腺癌风险分层的新见解。
Curr Opin Oncol. 2014 Jan;26(1):1-7. doi: 10.1097/CCO.0000000000000022.
2
Prognostic Factors in Differentiated Thyroid Cancer Revisited.再探分化型甲状腺癌的预后因素
Isr Med Assoc J. 2017 Feb;19(2):114-118.
3
Evaluating the influence of prophylactic central neck dissection on TNM staging and the recurrence risk stratification of cN0 differentiated thyroid carcinoma.评估预防性中央区颈淋巴结清扫术对cN0分化型甲状腺癌TNM分期及复发风险分层的影响。
Bull Cancer. 2016 Jun;103(6):535-40. doi: 10.1016/j.bulcan.2016.04.003. Epub 2016 May 25.
4
The Positive Lymph Node Number and Postoperative N-Staging Used to Estimate Survival in Patients with Differentiated Thyroid Cancer: Results from the Surveillance, Epidemiology, and End Results Dataset (1988-2008).用于评估分化型甲状腺癌患者生存率的阳性淋巴结数目及术后N分期：监测、流行病学与最终结果数据集（1988 - 2008年）的结果
World J Surg. 2018 Jun;42(6):1762-1771. doi: 10.1007/s00268-017-4343-6.
5
Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.同质管理的pT3分化型甲状腺癌人群中的复发风险。
Langenbecks Arch Surg. 2018 May;403(3):325-332. doi: 10.1007/s00423-018-1657-2. Epub 2018 Feb 14.
6
The impact of age on thyroid cancer staging.年龄对甲状腺癌分期的影响。
Curr Opin Endocrinol Diabetes Obes. 2018 Oct;25(5):330-334. doi: 10.1097/MED.0000000000000430.
7
NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk.N末端B型利钠肽原在分化型甲状腺癌患者中升高，可能预示心血管风险。
Clin Biochem. 2017 Aug;50(12):696-702. doi: 10.1016/j.clinbiochem.2017.02.020. Epub 2017 Feb 27.
8
Survival and death causes in differentiated thyroid carcinoma.分化型甲状腺癌的生存情况及死亡原因
J Clin Endocrinol Metab. 2006 Jan;91(1):313-9. doi: 10.1210/jc.2005-1322. Epub 2005 Nov 1.
9
Prognostic Factors for Early and Long-Term Remission in Pediatric Differentiated Thyroid Carcinoma: The Role of Sex, Age, Clinical Presentation, and the Newly Proposed American Thyroid Association Risk Stratification System.儿童分化型甲状腺癌早期和长期缓解的预后因素：性别、年龄、临床表现及新提出的美国甲状腺协会风险分层系统的作用
Thyroid. 2016 Oct;26(10):1480-1487. doi: 10.1089/thy.2016.0302. Epub 2016 Sep 22.
10
Risk and prognostic factors for differentiated thyroid cancer.分化型甲状腺癌的风险和预后因素。
Hell J Nucl Med. 2006 Sep-Dec;9(3):156-62.
引用本文的文献
1
Multi-Omics and Management of Follicular Carcinoma of the Thyroid.甲状腺滤泡癌的多组学与管理
Biomedicines. 2023 Apr 19;11(4):1217. doi: 10.3390/biomedicines11041217.
2
Changes in Stage Distribution and Disease-Specific Survival in Differentiated Thyroid Cancer with Transition to American Joint Committee on Cancer 8th Edition: A Systematic Review and Meta-Analysis.第八版美国癌症联合委员会分期系统对分化型甲状腺癌分期分布和疾病特异性生存的影响：系统评价和荟萃分析。
Oncologist. 2021 Feb;26(2):e251-e260. doi: 10.1634/theoncologist.2020-0306. Epub 2020 Sep 16.
3
Impact of gender on survival in patients with laryngeal squamous cell carcinoma: a propensity score matching analysis.性别对喉鳞状细胞癌患者生存的影响：一项倾向评分匹配分析。
Int J Clin Exp Pathol. 2020 Mar 1;13(3):573-581. eCollection 2020.
4
Microscopic extrathyroid extension in papillary thyroid carcinoma: impact on response to therapy.甲状腺乳头状癌的镜下甲状腺外扩展：对治疗反应的影响
Arch Endocrinol Metab. 2020 Apr;64(2):144-149. doi: 10.20945/2359-3997000000210. Epub 2020 Mar 27.
5
Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series.BRAF（V600E）突变与甲状腺乳头状癌临床病理特征之间的关联：一项巴西单中心病例系列研究
Arch Endocrinol Metab. 2019 Mar-Apr;63(2):97-106. doi: 10.20945/2359-3997000000120. Epub 2019 Mar 21.
6
Papillary thyroid carcinoma: different clinical behavior among pT3 tumors.甲状腺乳头状癌：pT3肿瘤的不同临床行为。
Endocrine. 2016 Sep;53(3):754-60. doi: 10.1007/s12020-016-0927-4. Epub 2016 Mar 21.
7
Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India.碘-131 摄取的分化型甲状腺癌远处转移：印度北部一家机构的初步经验。
Indian J Nucl Med. 2015 Jul-Sep;30(3):227-32. doi: 10.4103/0972-3919.158530.
本文引用的文献
1
Impact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate.年龄对前列腺小细胞癌患者临床表现、治疗和癌症特异性生存的影响。
Clin Interv Aging. 2013;8:871-7. doi: 10.2147/CIA.S44772. Epub 2013 Jul 10.
2
BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.甲状腺乳头状癌中的 BRAF 突变：对长期预后和放射性碘敏感性的预测价值。
Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Feb;131(1):7-13. doi: 10.1016/j.anorl.2013.01.004. Epub 2013 Jul 9.
3
The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.基于 Memorial Sloan-Kettering 癌症中心风险分组分层，探讨放射性碘选择性应用于甲状腺乳头状癌治疗管理中对生存和复发的影响。
Thyroid. 2013 Jun;23(6):683-94. doi: 10.1089/thy.2012.0307.
4
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.分化型甲状腺癌的预后与诊断时血清促甲状腺激素和甲状腺球蛋白抗体的状态有关。
Thyroid. 2014 Jan;24(1):35-42. doi: 10.1089/thy.2013.0062. Epub 2013 Sep 4.
5
Progress in molecular-based management of differentiated thyroid cancer.分化型甲状腺癌的分子靶向治疗进展。
Lancet. 2013 Mar 23;381(9871):1058-69. doi: 10.1016/S0140-6736(13)60109-9. Epub 2013 Mar 22.
6
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.BRAF V600E 突变与甲状腺乳头状癌患者死亡率的关系。
JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.
7
RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.甲状腺细针穿刺标本中的 RAS 突变高度提示以低危滤泡性癌为主。
J Clin Endocrinol Metab. 2013 May;98(5):E914-22. doi: 10.1210/jc.2012-3396. Epub 2013 Mar 28.
8
Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.根据美国甲状腺协会和拉丁美洲甲状腺学会复发风险分类系统对分化型甲状腺癌患者进行风险分层的结果。
Thyroid. 2013 Nov;23(11):1401-7. doi: 10.1089/thy.2013.0011. Epub 2013 Jul 25.
9
Recent trends in the incidence, geographical distribution, and survival from thyroid cancer in Wales, 1985-2010.近年来威尔士甲状腺癌的发病率、地理分布和生存率趋势，1985-2010 年。
Thyroid. 2013 Nov;23(11):1470-8. doi: 10.1089/thy.2012.0573. Epub 2013 Jun 14.
10
RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.切尔诺贝利核事故后甲状腺癌中的 RET/PTC 和 PAX8/PPARγ 染色体重排及其与碘-131 辐射剂量和其他特征的关系。
Cancer. 2013 May 15;119(10):1792-9. doi: 10.1002/cncr.27893. Epub 2013 Feb 21.
Zotero 插件